<?xml version="1.0" encoding="UTF-8"?>
<p id="Par98">The use of cannabis for symptom control continues to be a topical issue within medicine, and this study is the first placebo-controlled, randomised trial to assess the efficacy of cannabinoids in advanced cancer patients. A major strength of this study is that it will target symptom burden as a whole, rather than just individual symptoms, in an attempt to capture the improvement in general wellbeing reported anecdotally by many who have used cannabis [
 <xref ref-type="bibr" rid="CR23">23</xref>, 
 <xref ref-type="bibr" rid="CR24">24</xref>]. Randomisation with placebo is essential because of the well-documented overreporting of benefit in uncontrolled trials and high placebo response rates in cancer pain trials [
 <xref ref-type="bibr" rid="CR25">25</xref>, 
 <xref ref-type="bibr" rid="CR26">26</xref>]. The trial design is pragmatic, intended to allow as wide a range of participants as possible, to enable the results to be as real-world as possible. This study also allows for some data on dosing and formulation of THC/CBD specifically.
</p>
